AJANTPHARM

Ajanta Pharma Balance Sheet

₹3,575.70+0.06%
Market cap
₹44,673 crore
P/E
39.4
P/B
9.87
ROE
25.4%
Dividend yield
0.89%

As of Mar 2022, Ajanta Pharma had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 3,267.95% from Mar 2023.

Ajanta Pharma balance sheet

As at each financial year end, newest first. H1 = half-year.

Ajanta Pharma balance sheet (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital50025.2725.2725.0725.07
Reserves8,5003,1413,3143,6724,378
Borrowings1,20035.6335.2847.42260
Other liabilities3,5001,2551,0361,1771,368
Total liabilities13,7004,6794,6385,0156,155
Fixed assets6,5001,6981,7291,9002,121
Capital work in progress400100100100100
Investments2,5009369281,0031,231
Other assets4,3001,4041,3921,5041,846
Total assets13,7004,6794,6385,0156,155

Balance sheet ratios

Debt to equity
0.13

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Ajanta Pharma balance sheet — frequently asked questions

What is the total debt of Ajanta Pharma?

Ajanta Pharma reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹35.63 crore as of Mar 2023.

What is Ajanta Pharma's debt-to-equity ratio?

Based on the Mar 2022 balance sheet, Ajanta Pharma's debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.

What are Ajanta Pharma's total assets?

Ajanta Pharma's total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.

Same Data For Peers

Trade Ajanta Pharma With ATS

Track AJANTPHARM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.